NNC0130 is a new GLP-1R/GIPR dual agonist evaluated in a Phase 1 study. This NNC0130 Phase 1 report compares oral and subcutaneous delivery. The paper reports a clear contrast: oral exposure produced modest weight change, while the subcutaneous cohorts showed larger effects over the short study period. Those findings matter for research because they show how delivery can shape the interpretation of the same peptide design.
Contents
NNC0130 and the dual-receptor design
The study describes NNC0130 as a unimolecular, fatty-acylated peptide designed to activate the human GLP-1 and GIP receptors. The researchers first screened a panel of candidates in cell-based receptor assays. They selected NNC0130 for further development because its in vitro potency was comparable to semaglutide at the human GLP-1 receptor and to tirzepatide at the human GIP receptor. These comparisons describe assay findings, not a claim that the molecules are interchangeable.
The chemical design was also intended to support semi-recombinant production. In people, the reported half-life was 76 to 89 hours. The authors considered that duration compatible with once-daily administration in the clinical programme. Half-life, receptor potency and oral exposure are different measurements, so they should not be treated as substitutes for one another when reading the paper.
What the Phase 1 study tested
The multiple-ascending-dose trial included participants with overweight or obesity and separate oral and subcutaneous cohorts. The subcutaneous groups received daily doses that escalated from 0.3 to 3.0 mg per dose. The oral groups received daily doses that escalated from 5 to 50 mg per dose. The trial therefore examined more than receptor activity: it also tested how formulation and route affected exposure during repeated dosing.
Because the report is an early clinical study, its results should be read with the study design and duration in view. A short Phase 1 programme can provide pharmacology and safety information while leaving larger questions for later trials. It does not establish long-term outcomes or make a research reagent suitable for human use.
Why the oral and subcutaneous results diverged
After 12 weeks, daily subcutaneous administration was associated with a placebo-corrected mean body-weight change of 9 percent, and the reported figure reached 12 percent after 15 weeks. Daily oral administration was associated with a placebo-corrected mean change of 4 percent after 12 weeks, and that result was not statistically significantly different from zero. These are the authors’ clinical findings, not a performance claim for any laboratory product.
The paper links the difference to the difficulty of delivering acylated peptides through the gastrointestinal tract. When formulated with the permeation enhancer salcaprozate sodium, relative oral bioavailability was estimated at 1.6 to 2.2 percent compared with subcutaneous administration. The result is a useful reminder that oral convenience does not automatically translate into adequate systemic exposure.
What researchers should take from the paper
The most useful lesson is methodological. Receptor potency measured in cells cannot predict the final performance of a delivery route on its own. A candidate may have strong activity in a cell assay and still show limited oral bioavailability. Conversely, a subcutaneous result cannot be transferred to an oral formulation without evidence from pharmacokinetics and controlled clinical comparison.
The paper also illustrates why formulation, exposure and endpoint should be reported together. The route, dose range, participant group, follow-up period and statistical comparison all affect interpretation. For laboratory research, these variables are more informative than a single headline number.
Related on Peptra Labs
For background on the receptor biology and published research context, see the tirzepatide research guide. The tirzepatide catalogue page is a separate research-material reference and is not NNC0130. Both links should be read without treating a laboratory reagent as the authorised pharmaceutical product discussed in a clinical paper.
References
- Discovery, optimization, and Phase 1 evaluation of a novel, orally available GLP-1R/GIPR dual agonist. Molecular Metabolism. 2026. PubMed 42977258. DOI: 10.1016/j.molmet.2026.102470.
- Primary abstract and bibliographic record.
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
